The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

The FDA has granted full approval to Precigen’s Papzimeos (zopapogene imadenovec-drba) for adults with recurrent respiratory papillomatosis (RRP). Papzimeos is a non-replicating adenoviral ...

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful ...

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.